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Targeted therapy has evolved recently as an important
treatment modality for cancer, and the most extensively
studied pathways for targeted therapy are those related to
epidermal growth factor receptor (EGFR). EGFR is widely
expressed in diﬀerent tumor types and strong expression is
associated with higher risk of recurrence/metastasis, poorer
survival, and resistance to chemotherapy/radiotherapy. Both
monoclonal antibody against EGFR and/or tyrosine kinase
inhibitors are now in use clinically for treatment of advanced
cancer. With the increasing usage of these agents and the
availability of more new agents in the future, knowledge on
anti-EGFR therapy is highly relevant to the current state of
cancer therapy and to new research directions in the ﬁeld of
oncology.
The focus of this special issue is on the clinical applica-
tions of approved or investigational anti-EGFR therapy in
solid tumors with emphasis on eﬃcacy, toxicity, response,
assessment, multimodality treatment, prognostic factors and
predictivemarkers.ThereviewbyA.Harandietal.providesa
comprehensive and updated overview of the frequently used
EGFR inhibitors and summarizes clinical eﬃcacy data of
these agents and their associated toxicity and management.
This review clearly shows the impact of anti-EGFR therapy
on cancer treatment since improved treatment results can be
seen with the use of anti-EGFR therapy in many common
cancers. One of these cancers is colorectal cancer and
the approval of anti-EGFR monoclonal antibodies in the
treatment of metastatic colorectal cancer has expanded the
armamentarium against this disease. H. Loong et al. in their
review summarize the historical progress and recent clinical
developments of anti-EGFR therapies in the treatment of
metastatic CRC and discuss the novel strategies of targeting
the EGFR pathway to improve eﬃcacy as well as ongoing
research in identifying speciﬁc molecular predictors of
response.
While the approved use of drugs like the dual kinase
inhibitor Lapatinib represents signiﬁcant advances in the
clinical management of breast cancer, conﬁrmatory studies
must be considered to foster the use of anti-EGFR therapies
including safety, pharmacokinetics, and clinical eﬃcacy in
this common cancer. The article by J. Flynn et al. reviews
the mechanism of anti-EGFR therapy in breast cancer and
summarizes recent advances including the development of
improved high-throughput analyses for identifying novel
anti-EGFR activity, as well as advances in DNA/RNA-
microarray technology for classiﬁcation purposes, which will
contribute to the overall understanding and development of
targeted therapy in treatment of breast cancer.
Cancers of the esophagus and stomach present a major
health burden worldwide. The impact of cytotoxic agents on
the disease has been modest. EGFR pathway has also been
implicated in pathophysiology of esophageal and stomach
cancers. Recently EGFR inhibitors have been explored in
patients with esophageal and gastric cancers, and the results
are summarized by T. Dragovich and C. Campen in their
review. It also appears that tumors of the distal esophagus
and gastroesophageal junction are more sensitive to EGFR
blockade than distal gastric adenocarcinoma.
Similar to cytotoxic agenst, drug resistance remains an
important issue and research ﬁeld in targeted therapy. The
article by J. Rolﬀ et al. studied the impact of diﬀerent
resistance markers at protein and mRNA level in patient-
d e r i v e dn o n s m a l lc e l ll u n gc a n c e rx e n o g r a f t si nr e s p o n s e
to erlotinib and other cytotoxic agents. The results suggest2 Journal of Oncology
that the expression levels of multidrug resistant proteins and
mRNA do not play an important role in the drug resis-
tance of nonsmall cell lung cancer. Increased transforming
growthfactor-β (TGF-β)expressionandEGFRampliﬁcation
accompany the emergence of highly aggressive human
carcinomas, and cooperative signaling between these two
growth factor/receptor systems promotes cell migration and
synthesis of stromal remodeling factors that in turn regulate
tumor invasion, neo-angiogenesis and inﬂammation. R.
Samarakoon et al. studied the role of plasminogen activator
inhibitor-1 in carcinogensis and explored its potential role
as a novel therapeutic target in combination with EGFR
inhibition.
We hope that this special issue will stimulate interests
andnewresearchesinthedevelopmentofanti-EGFRtherapy
in cancers, particularly the development of personalized
medicine based on predictive biomarkers so that therapy can
be tailored and optimized in every patient.
Daniel Chua
Peter Fasching
Brigette Ma
Sumitra Thongprasert
Lori Wirth